Zydus Lifesciences gets grant for oral suspension pharmaceutical composition of immunosuppressive agent
According to GlobalData’s company profile on Zydus Lifesciences, NSAID cancer drugs was a key innovation area identified from patents. Zydus Lifesciences's grant share as of February 2024 was 71%. Grant share is based on the ratio of number of grants …